|
|
Request Number: 5.1
Client Pbio
We have an immediate need to license early stage drug candidates, preferably those having companion diagnostic procedures. Particular interest is in cardiovascular, dyslipidemia, diabetes, metabolic syndrome, obesity, osteoporosis, and arthritis technologies, with no interest in infectious diseases, oncology, CNS, respiratory, or dermatology. Technologies that have been proven to be efficacious in animal models are desired. The technology should have Intellectual Property protection. Our client is a public, entrepreneurial company looking to enhance its intellectual property.
Primary Focus Areas: Cardiovascular, Dyslipidemia, Diabetes, Metabolic Syndrome, and Obesity Technologies
- Diagnostics: DNA- and RNA-based methods, biomarkers, and diagnostic
- devices.
- Therapeutics: Early-stage drugs.
- A combination of drug candidates and companion diagnostics is preferred.
Secondary Focus Area: Osteoporosis, Osteoarthritis, and Rheumatoid Arthritis Technologies
- Diagnostics: DNA- and RNA-based, biomarkers, and diagnostic devices.
- Therapeutics: Early stage drugs.
- A combination of drug candidates and companion diagnostics is preferred.
Please contact the Office of Technology Management if you have any technology that may be relevant to this request. |